Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study.

ABSTRACT:

Background

Mucositis is a common and highly impactful side effect of conventional and emerging cancer therapy and thus the subject of intense investigation. Although common practice, mucositis assessment is heterogeneously adopted and poorly guided, impacting evidence synthesis and translation. The Multinational Association of Supportive Care in Cancer (MASCC) Mucositis Study Group (MSG) therefore aimed to establish expert recommendations for how existing mucositis assessment tools should be used, in clinical care and trials contexts, to improve the consistency of mucositis assessment.

Methods

This study was conducted over two stages (January 2022-July 2023). The first phase involved a survey to MASCC-MSG members (January 2022-May 2022), capturing current practices, challeng

SUBMITTER: Abdalla-Aslan R 

PROVIDER: S-EPMC11200283 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature